New Alzheimer's drug candidate begins safety testing in healthy volunteers

NCT ID NCT07016464

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety and tolerability of a new medicine called REM0045392, being developed for Alzheimer's disease. The study involved 19 healthy adults, including younger men and older men and women, who received either the drug or a placebo. The trial was terminated, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

REM0045392

What this could lead to

If successful, this could lead to a new treatment option for Alzheimer's disease.

What could go wrong

This is a very early Phase 1 trial in healthy people, not Alzheimer's patients. The study was terminated, so results may be incomplete. Many early-stage drugs fail to show benefit in later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • SGS Belgium NV - Clinical Pharmacology Unit

    Edegem, 2650, Belgium